Trials / Unknown
UnknownNCT05042401
A Trial of SHR-1703 in Asthma
Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of a Single Subcutaneous Injection of SHR-1703 in Patients With Asthma -- a Randomized, Double-blind, Dose-increasing, Placebo Controlled Phase I Clinical Study
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 23 (actual)
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
SHR-1703 is a monoclonal antibody under development for severe asthma. This study is the first study in patients with asthma. The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics ，pharmacodynamics and immunogenic characteristics of multiple subcutaneous injections of SHR-1703 in asthmatic patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-1703 | SHR-1703 low dose |
| DRUG | placebo | placebo low dose |
| DRUG | SHR-1703 | SHR-1703 high dose |
| DRUG | placebo | placebo high dose |
Timeline
- Start date
- 2021-10-12
- Primary completion
- 2023-06-15
- Completion
- 2023-06-15
- First posted
- 2021-09-13
- Last updated
- 2023-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05042401. Inclusion in this directory is not an endorsement.